Nearly all adults with Down syndrome will develop indications of Alzheimer’s Disease (AD) by as early as 40 years old, including amyloid plaque on the brain. Lecanemab is a drug designed to target and remove amyloid plaque, and recently approved by the U.S. Food and Drug Administration. However, people with Down...
Biobanking: What It Is & Why You Should Care
Biobanks continue to evolve over time.What started out as simple biological and environmental repositories for various sample collections continues to expand into large infrastructure collection points for studying cancer, diseases, and human conditions like Down syndrome.At DownSyndrome Achieves, we continue to advocate for Down syndrome research. We created the DSA...
Breaking Barriers: Improving Healthcare Experiences for People with Down Syndrome
by: Angela McPhillips, DNP RN People with Down syndrome (DS) face unique challenges in healthcare settings. Sometimes the healthcare team skillfully meets these challenges. Other times, the experience is frustrating for the person with Down syndrome, their caregiver, and healthcare providers. What are some common challenges in healthcare settings that people...
DownSyndrome Achieves Completes Delivery of Biosamples for Study Investigating Prevalence of Eye Disease in People with DS
DownSyndrome Achieves is pleased to announce it has completed the delivery of 100 blood plasma and serum samples for an NIH-funded R21 study on keratoconus dystrophy (KD) and Down syndrome at the University of North Texas Health Science Center at Fort Worth.Keratoconus dystrophy is a corneal disease that affects more...
Lee Specialty Clinic Joins DSA Biobank to Advance Research for People with DS
DownSyndrome Achieves (DSA) is pleased to announce its partnership with Lee Specialty Clinic in Louisville, Kentucky, which will be the first collection site of biospecimen for the organization’s DSA Biobank initiative. Lee Specialty Clinic is one of only a handful of comprehensive healthcare facilities in the US that serves exclusively...
DownSyndrome Achieves CEO, Lito Ramirez, Joins National Campaign Urging Continued Funding for Research Innovation
https://youtu.be/7v-j8tX9Tyk Lito Ramirez: Sacrificing even one future medicine is unacceptable DownSyndrome Achieves, CEO, Lito Ramirez, recently appeared in a national television ad campaign called "Voters for Cures" which urges balancing the need for affordable drugs and the need for research innovations.